BRAF V600 Mutation Clinical Trial
Official title:
An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib.
The purpose of this study is to evaluate the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib.
Melanoma is a heterogeneous skin tumor, characterized by mutations of different oncogenes. Almost half of patients with advanced melanoma have a gene mutation of BRAF serine-threonine kinase. Over the past 5 years, two BRAF inhibitors targeting these mutations, vemurafenib and dabrafenib, have shown high rates of rapid response in phase II and III studies. However, the duration of responses is limited in most patients due to the development of acquired resistance. Mechanisms of resistance to BRAF inhibitor therapy are diverse and include the reactivation of the mitogen-activated protein kinase (MAPK) pathway in over two-thirds of tumors, along with promotion of parallel signaling networks. Recently, the combination of drugs was superior in terms of responses, Progression Free Survival (PFS) and Overall Survival (OS) compared to monotherapy. The data from recent studies confirm the clinical benefit of the combination of Vemurafenib with cobimetinib and support the use of the combination as a standard first-line approach to improve survival in patients. The aim of this randomized, open-label, phase II study is to evaluate the efficacy, in terms of overall survival, of vemurafenib combined with cobimetinib associated with local treatment compared with second-line therapy, in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Active, not recruiting |
NCT05103891 -
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Recruiting |
NCT05501912 -
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05510895 -
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03663647 -
Advanced Melanoma in Russian Experience
|
||
Recruiting |
NCT04741997 -
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
|
Early Phase 1 | |
Completed |
NCT04775095 -
BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
|
||
Recruiting |
NCT05546905 -
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
|
||
Terminated |
NCT04190628 -
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03430947 -
Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases
|
Phase 2 | |
Withdrawn |
NCT04759846 -
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
|
Phase 1 | |
Recruiting |
NCT04911998 -
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
|
||
Not yet recruiting |
NCT06054191 -
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
|
Phase 2 | |
Not yet recruiting |
NCT05275374 -
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT05810740 -
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
|
Phase 1 | |
Recruiting |
NCT05800340 -
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
|
Phase 2 | |
Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 |